구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | L19TNF | L19IL2/L19TNF |
Overview Company | Philogen S.p.A. | Philogen S.p.A. |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Melanoma Stage III | Melanoma Stage III |
Overview Indication | Melanoma Stage III; Melanoma Stage IV | Melanoma Stage III; Melanoma Stage IV |
Overview Phase | PHASE_2 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational |
Toxicology Major finding | Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.. L19TNF is a recombinant fusion protein composed of a human antibody fragment and human tumour necrosis factor. L19TNF targets the EDB domain of oncofetal fibronectin highly expressed in tumour vasculat… | — |
Clinical Safety signal | Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.. L19TNF is a recombinant fusion protein composed of a human antibody fragment and human tumour necrosis factor. L19TNF targets the EDB domain of oncofetal fibronectin highly expressed in tumour vasculat… | — |
Clinical Program phase | PHASE_2 | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | L19TNF | L19IL2/L19TNF |
Overview Company | Philogen S.p.A. | Philogen S.p.A. |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Melanoma Stage III | Melanoma Stage III |
Overview Indication | Melanoma Stage III; Melanoma Stage IV | Melanoma Stage III; Melanoma Stage IV |
Overview Phase | PHASE_2 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational |
Toxicology Major finding | Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.. L19TNF is a recombinant fusion protein composed of a human antibody fragment and human tumour necrosis factor. L19TNF targets the EDB domain of oncofetal fibronectin highly expressed in tumour vasculat… | — |
Clinical Safety signal | Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.. L19TNF is a recombinant fusion protein composed of a human antibody fragment and human tumour necrosis factor. L19TNF targets the EDB domain of oncofetal fibronectin highly expressed in tumour vasculat… | — |
Clinical Program phase | PHASE_2 | PHASE_2 |
추천 비교
추천 비교